On Wednesday, Shares of Groupon, Inc. (NASDAQ:GRPN), gained 1.99% to $6.15.
Groupon, declared it has named Rich Williams as Chief Operating Officer to oversee its global businesses and operations. Williams presently serves as President of North America and will continue in that capacity while adding responsibility for Groupon’s international regions.
The leadership teams for EMEA, Rest of World and Global Operations will report to Williams, in addition to his current team.
Williams joined Groupon in 2011, first serving as Groupon’s Chief Marketing Officer. Throughout his 20-year career, he has overseen some of the largest online marketing programs in the world and the analytics and technology that power them. Preceding to joining Groupon, he held a variety of marketing and leadership roles at Amazon and Experian.
Groupon also declared that Chief Financial Officer Jason Child will be leaving the company at the end of July to relocate to the west coast.
Groupon, Inc. operates online local commerce marketplaces that connect merchants to consumers by offering goods and services at a discount worldwide. It also offers deals on products for which it acts as the merchant of record.
Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX), inclined 14.79% to $26.62, during its last trading session, hitting its highest level.
Heron Therapeutics, declared that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at JMP Securities 2015 Life Sciences Conference in New York, NY. Presentation: Tuesday, June 23, 2015 at 4:30 p.m. ET (1:30 p.m. PT).
Heron Therapeutics, Inc. is a biotechnology company using its proprietary technology and innovative efforts to develop products to address unmet medical needs. The Company’s proprietary Biochronomer drug delivery technology is designed to improve the therapeutic profile of injectable pharmaceuticals.
At the end of Wednesday’s trade, Shares of Nuance Communications, Inc. (NASDAQ:NUAN), gained 6.67% to $17.90.
Nuance Communications, declared the general availability of PowerScribe 360® Reporting version 3.0, delivering the industry’s first integrated computer-assisted reporting solution at the point of clinical documentation for radiologists. PowerScribe 360, the leading radiology reporting and communication platform, enables radiologists to create higher quality reports supported by real-time, evidence-based clinical guidance using content developed by the American College of Radiology (ACR). Coupled with quality check tools, PowerScribe preserves radiologists’ natural workflow, and provides referring physicians and patients with more consistent recommendations following an exam. Nuance PowerScribe 360 Reporting 3.0 was tested in advance of its release by Albert Einstein Medical Center in Philadelphia, in addition to The Mount Sinai Hospital — Mount Sinai St. Luke’s and Mount Sinai Roosevelt in New York, and is now accessible for the broader radiology community.
“Having all of the recommendations embedded into PowerScribe adds tremendous value, and has the potential to dramatically improve radiology reports across the country,” said Terence Matalon, MD, chairman of the department of radiology, Einstein Healthcare Network. “The ease of inserting evidence-based guidelines into clinical documentation is unique in the marketplace, yielding a more consistent report based on patient outcomes. Having such guidelines one click away is a game changer and extremely helpful in managing and justifying decision making for patient care.”
Nuance Communications, Inc. provides voice and language solutions for businesses and consumers worldwide. It offers hosted and on-premise solutions and services that provide platforms to generate and distribute clinical documentation through the use of dictation and transcription features; clinical documentation improvement programs; and speech recognition solutions for radiology, cardiology, pathology, and related specialties enabling healthcare providers to dictate, edit, and sign reports without manual transcription.
Finally, Retrophin, Inc. (NASDAQ:RTRX), ended its last trade with 3.56% gain, and closed at $32.86, hitting its highest level.
Retrophin, declared a contract to sell its Rare Pediatric Disease Precedingity Review Voucher to Sanofi (SNY). Retrophin received the Pediatric PRV when Cholbam™ was approved by the U.S. Food and Drug Administration (FDA) for the treatment of pediatric and adult patients suffering from bile acid synthesis disorders due to single enzyme defects, and for patients with peroxisomal disorders (counting Zellweger spectrum disorders).
Upon closing of the transaction, Retrophin will receive a payment of $150 million, followed by two equal installments of $47.5 million in 2016 and 2017. The Company will receive a total consideration of $245 million in cash from Sanofi in exchange for the Pediatric PRV. The voucher was awarded by the FDA under a provision that encourages development of new drugs and biologics for the prevention and treatment of rare pediatric diseases.
The transaction is subject to customary closing conditions and clearance under the Hart-Scott-Rodino Antitrust Improvements Act.
Retrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of serious, catastrophic, or rare diseases. Its product line comprises Cholbam, a cholic acid for the treatment of bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of peroxisomal disorders, such as Zellweger spectrum disorders in patients who exhibit manifestations of liver disease, steatorrhea, or complications from reduced fat soluble vitamin absorption.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
